Clinical Significance Of ATP-tumor Chemosensitivity Assay (ATP-TCA) In Chemotherapy Of Advanced Breast Cancer

Objective:1. To study whether ATP chemosensitivity assay(ATP-TCA) test can direct clinical chemotherapy.2. ATP in vitro method to explore whether there is any experimental drugs to reduce toxicity.Methods:1. 56 cases of patients with non-surgical advanced breast cancer patients were tested by the ATP-TCA as the research group; The other 56 cases of patients with non-surgical advanced breast cancer patients weren't tested by the ATP-TCA as the control group. Compare two group's clinical outcome after six cycles'(one cycle for twenty-one days) chemotherapy.2. The two groups in the first 2 cycles (1 cycle 21d) after treatment compared toxicity .Results:1. The overall response rate of the research group was 86%(48/56) ,the control group was 49%(27/56). The research group shows better than the control group in alleviating symptoms, decreasing tumor size ,cutting down tumor markers of breast cancer such as CEA,CA15-3 and so on. In the research group,more than one year survival period was 83%(46/56);Correspondingly,th control group is 61%(34/56).The research group is more significantly than the control group in Clinical effect ( P<0.05).2. Study group and control group toxicity of mainly bone marrow suppression, gastrointestinal reactions, alopecia and mucositis. Reaction in which the digestive tract was significantly (P<0.05), and bone marrow suppression, alopecia and mucositis was no significant difference.Conclusions: 1. The ATP—TCA has preferable value to direct the chemotherapy of advanced breast cancer,which can prolong the survival period , which can improve the clinic curative effect.2. ATP in vitro tumor cell culture + sensitivity test of advanced breast cancer chemotherapy drug can avoid the use of ineffective drugs toxicity.